AstraZeneca's first quarter profits jump 74%

LONDON — Anglo-Swedish drugmaker AstraZeneca says first quarter earnings jumped 74%, buoyed by emerging markets and the success of new cancer treatments.

AstraZeneca said Friday that net income rose to $593 million from $340 million in the same period last year. Product sales increased 5.5% to $16.39 billion, driven by new drugs such as the bladder cancer treatment Imfinzi and lung cancer therapy Tagrisso.

Emerging market sales increased 14%, boosted by strong growth in China.

Nicholas Hyett, equity analyst at Hargreaves Lansdown in London, says the results vindicate CEO Pascal Soriot's strategy and show that "revenue growth is no longer a matter of faith" for investors.

Soriot promised investors that AstraZeneca's pipeline of new drugs would pay off when he fended off a takeover bid from Pfizer in 2014.

Must Read

Duchess of Cambridge meets families at children's...

Jan 24, 2017

The Duchess of Cambridge has paid an emotional visit to a children's hospice in a village northeast...

'A truly magnificent talent:' actor John Hurt...

Jan 28, 2017

As a self-described "old drunk," the actor John Hurt nonetheless had a half-century career...

Trump state visit plans put queen in 'difficult...

Jan 31, 2017

The British government's decision to invite President Donald Trump for a state visit, one of the...

UK pardons thousands convicted under past...

Jan 31, 2017

Thousands of men convicted under now-abolished anti-homosexuality laws in Britain have been...

Homelessness activists evicted from pricey...

Feb 1, 2017

British authorities have evicted a group of squatters who moved into a vacant mansion in one of...

Sign up now!